Funding for this research was provided by:
tibet cheezheng tibetan medicine co., ltd. (not applicable)
Innovation Team and Talents Cultivation Program of National Administration of Traditional Chinese Medicine (ZYYCXTD-C-202006, ZYYCXTD-C-202006)
Project of Methodological research combining quantitative and qualitative research on the effects and risks of Chinese patent medicines (2180072120104, 2180072120104)
Received: 11 July 2021
Accepted: 23 April 2022
First Online: 12 May 2022
: This study has obtained the ethics approval from the Ethics Committee of Fangshan Hospital, Beijing University of Chinese Medicine on September 18, 2020 (Reference No. FZY LK-2020-015); from the Ethics Committee of The Second Affiliated Hospital of Zhejiang Chinese Medical University on January 26, 2021 (Reference No. 2020-Y-003-IH01); and from the Ethics Committee of Liuzhou People’s Hospital on April 26, 2021 (Reference No. GCP2021-015-01). Before participating, all participants will be fully informed of the trial and sign an informed consent.
: Not applicable.
: The authors declare that they have no competing interests.